Friday, 19 Jan 2018

You are here

Uveitis Events Reduced with Select TNF Inhibitors

Uveitis may occur in up to 40% of spondyloarthritis patients. Metanalyses have shown that treatment with tumour necrosis factor-α inhibitor (TNFi) may reduce the rates of anterior uveitis (AU).  A multicenter study from Sweden and Norway has confirmed that amongst TNFi, adalimumab (ADA) and infliximab (IFX) offer better protection against AU than etanercept (ETN).

Real world data was extracted from the Swedish Rheumatology Quality Register and examined ankylosing spondylitis patients from multiple centers starting ADA, ETN or IFX as their first TNFi between 2003 - 2010. The study included 1365 ankylosing spondylitis patients (406 ADA, 354 ETN, 605 IFX), and they examined AU rates prior to and after TNFi initiation.

AU rates with ADA and IFX therapy were decreased, while ETN was associated with an increase compared to pretreatment rates. The adjusted HRs for AU on ETN were higher compared to ADA and IFX (ETN HR: 3.86 95% CI 1.85 to 8.06; IFX HR: 1.99, 95% CI 1.23 to 3.22). There were no differences in rates seen between IFX and ADA.

These real world data confirm prior collective observations suggesting that monoclonal antibody based TNFi (ADA, IFX) have a clear advantage over ETN in preventing uveitis. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Why TNF Inhibitors May Work in Some Autoinflammatory Patients

The NLRP3 inflammasome is a critical component of the innate immune system and activation of NLRP3 inflammasome results in caspase-1–dependent secretion of the proinflammatory cytokines IL-1β and IL-18. Gain-of-function missense mutations in NLRP3 is thought to drive many of the autoinflammatory diseases, especially the cryopyrin-associated periodic syndromes (CAPS).

Infliximab Does Not Increase Perioperative Infection

Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (  On the other hand, discontinuation of the TNFi prior to surgery is associated with lower rates of  infection (

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

Amgen-Abbvie Settle Humira Biosimilar Patent Dispute

Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).